US FDA Approves Novo Nordisk's Diabetes Drug to Reduce Risk of Worsening Kidney Disease
(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
Here are some of the major companies whose stocks moved on the week’s news.
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...
President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback